Joseph Ngonzi
ID: UNCST-2019-R001579
|
Automated visual evaluation and geospatial mapping for cervical cancer screening optimization in sub-Saharan Africa (AVE-Map)
REFNo: HS2069ES
3. To use AVE and geospatial analysis to scale up cervical cancer screening in Uganda ,2. To determine access to cervical cancer screening and referral pathways in Uganda ,1. To validate and expand use of AVE for cervical cancer screening in SSA ,We aim to leverage and develop data science expertise at our sites to first optimize and then combine AVE-based screening by health workers at peripheral health facilities with geospatial-analysis and needs-driven assessment to inform scale-up of cervical cancer screening in Uganda ,
|
,
Mbarara, Kakoba
|
Uganda |
2022-02-28 |
2025-02-28 |
2000 |
Females aged 25 years and above |
NATIONAL INSTITUTE OF HEALTH |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Musa Sekikubo
ID: UNCST-2021-R014010
|
A placebo controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants
REFNo: HS1991ES
1. To describe the safety and tolerability of GBS6 when administered at ? 27 0/7 to ? 35 6/7 weeks’ gestation to pregnant women, with and without HIV, aged ? 18 to ? 40 years of age and their infants..
2. To assess the safety of GBS6 in infants born to HIV positive and negative women who were vaccinated during pregnancy.
|
Kampala, Kawempe
Kampala, Kisenyi
|
Uganda |
2022-02-11 |
2025-02-11 |
300 |
pregnant women aged 18 to 40 years at gestation age of ? 27 0/7 to ?35 6/7 weeks. |
St George’s, University of London Cranmer Terrace SW17 0RE |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Aisha Nanyiti
ID: UNCST-2021-R013489
|
A Randomized Control Trial (RCT) on the Adoption of Liquefied Petroleum Gas (LPG) Cooking Technology among Fast Food (Chapati) Vendors in Uganda
REFNo: SS1017ES
This study seeks to establish the impact of hire purchase schemes and health and safety information on adoption of LPG cookstoves by chapati vendors.
This study will achieve the following specific objectives:
1) The impact of learning from LPG use in grace period before purchase armotisation on adoption of LPG cookstoves by chapati vendors for their businesses and households.
2) The impact of hire purchase on adoption of LPG cookstoves by chapati vendors for their businesses and households.
3) The impact of information on safety and health benefits of LPG on adoption of LPG cookstoves by chapati vendors for their businesses and households.
4) The impact of peer learning from other vendors using LPG cookstoves on adoption of LPG cookstoves by chapati vendors for their businesses and households.
|
Kampala,
|
Uganda |
2022-02-10 |
2025-02-10 |
210 |
chapatti vendors; they are mainly males of age range in 18-45 years from all districts of Uganda. |
Environment for Development Initiative |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Robert Kalyesubula
ID:
|
Effectiveness of a community health worker delivered care intervention for hypertension control in Uganda: a stepped wedge, cluster randomized control trial.
REFNo: HS1917ES
To assess the effectiveness of a CHW-delivered intervention for hypertension control in Uganda.,
|
Nakaseke, Kigegge, Bulwadda, Mifunya, Kyamutakasa, Kasambya, Kasagga, North Ward. East Ward. Namilali, Kivule Central Ward
|
Uganda |
2022-02-10 |
2025-02-10 |
900 |
Hypertensive patients, 18 years and above, attending Nakaseke hospital or Life Care NCD clinics, and residing either in Nakaseke town council, Nakaseke Subcounty or Kasangombe. |
Else Kroner Fresenius Stiftung |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Ssewamala
ID: UNCST-2020-R014060
|
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma on HIV Treatment Outcomes among Adolescents Living with HIV in Uganda
REFNo: SS1166ES
Aim 1: Examine the impact of M-Suubi on HIV viral suppression (primary outcome); and adherence to HIV treatment (keeping appointments, pharmacy refills, pill counts), and retention in care (secondary outcome).
Aim 2: Examine the effect of M-Suubi on Stigma (internalized anticipated, and enacted), with secondary analyses to explore hypothesized mechanisms of change (e.g. depression) and intervention mediation.
Aim 3: Assess the cost and cost-effectiveness of each intervention condition.
Aim 4: Qualitatively examine: a) participants’ experiences with HIV stigma, HIV treatment adherence, and the intervention; and 2) educators’ attitudes towards ALHIV and experiences with GED-HIVSR, and program/policy implementation post-training.
Aim 5: Conduct formative work (focus group discussions) to understand the needs of depressed ALHIV.
|
Masaka, Kimaanya
Kalungu, Bukulula
Rakai, Kakuuto TC
Lyantonde, Lyantonde TC
Bukomansimbi, Butenga
Lwengo, Lwengo
|
Uganda |
2022-02-04 |
2025-02-04 |
840 dyads |
The target populations for this study will be ALHIV, their caregivers (N=840 child-caregiver dyads), and administrators attending 42 boarding schools in the greater Masaka region. Participants will be included in the study if they meet the following inclu |
National Institute of Mental Health (NIMH) |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Emmy Okello
ID: UNCST-2020-R009792
|
Remote Ischaemic Conditioning in STEMI patients in sub-Saharan AFRICA: The RIC-AFRICA trial
REFNo: HS1865ES
RIC will reduce the rates of all-cause death and early post-myocardial heart failure by approximately 25% when compared to sham control.,The RIC-AFRICA trial will investigate the effect of RIC in STEMI patients on the rates of all-cause death and early post-MI heart failure (pre-discharge HF and hospitalisation for HF at 30 days post-MI,) when compared to sham control,
|
,
Kampala, MULAGO
|
Uganda |
2022-02-01 |
2025-02-01 |
1500 |
Participants will be recruited from the Uganda Heart Institute and other nearby
state and private hospitals with STEMI care with in Uganda and other
collaborating sites in Sub-Saharan countries
|
Mancherje-Potash Foundation, USA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jackson Mukonzo
ID: UNCST-2021-R013916
|
Safety and Efficacy of COVIDEX™ Therapy in Management of adult Covid-19 Patients in Uganda: A randomized double-blind placebo controlled adaptive phase 2 B clinical trial.
REFNo: HS2041ES
3. To determine the plasma concentration of berberine in COVID-19 patients receiving COVIDEX. ,2. To determine the efficacy of COVIDEXTm for treatment of COVID-19 among adults in Uganda.,To determine the efficacy of COVIDEXTm for treatment of COVID-19 among adults in Uganda.,To validate the safety and determine the efficacy of COVIDEXTm therapy for treatment of COVID-19 in adult Ugandans. ,
|
Mbarara, kakoba
Kampala, mulago 1
|
Uganda |
2022-01-25 |
2025-01-25 |
584 |
Participants who are categorized as mild score 2 (limitation of activities), moderately ill COVID-19 patients score 3 (Hospitalized with no oxygen therapy), score 4(Hospitalized with oxygen by mask or nasal prongs) and hospitalized severe disease score 5 |
JENA HERBALS LTD, MINISTRY OF HEALTH UGANDA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Susanne Guidetti Gittel Eleonora
ID: UNCST-2021-R012422
|
Participation in everyday life - A randomized controlled trial of
mobile phone-supported and family-centred rehabilitation after
stroke in Uganda
REFNo: HS1528ES
General objective (Overall aim)
To implement and evaluate the effects a mobile phone supported and family-centred rehabilitation intervention F@ce 2.0 aiming to enable performance in daily activities and participation in everyday life among persons who have had a stroke and their family members both in urban (Kampala and its surroundings) and rural (Greater Masaka) areas.
Specific objectives
• To describe the perceived impact of stroke and perceived participation in everyday life in a sample of people with stroke in rural Uganda. (Study 1)
• To evaluate the effects of F@ce in comparison with ordinary rehabilitation among persons with stroke in urban and rural Uganda regarding a) self-efficacy b) perceived performance and participation in everyday activities c) independence in ADL, d) healthcare utilization and e)their families´ perceived participation in everyday activities.(Study 2)
• To explore and describe the experiences of people with stroke and family members of participating in the F@ce (Study 3)
• To evaluate the implementation process of F@ce and to gain knowledge on the mechanisms of impact as well as the contextual factors that might influence the implementation process and its outcome. (Study 4)
• To determine the cost of delivering the F@ce intervention in comparison with the usual rehabilitation (Study 5)
|
Kampala,
Masaka,
Iganga,
|
Sweden |
2022-01-19 |
2025-01-19 |
174 |
The sample size will accommodate for an attrition rate of 10%, based on our pilot study in Uganda, therefore will require the inclusion of a total of 174 participants with stroke, 15 health professionals and 15 caregivers (family members). The study will |
The Swedish Research Council |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Maria NAKACHWA
ID:
|
Mobile Telephone Communication and Utilization of Antenatal Care Services During Pregnancy. A Case Study of Kyotera and Rakai Districts- Uganda
REFNo: HS1957ES
d. To develop a model for the prediction of ANC uptake when mobile telephone communication is used.,c. To evaluate effects of patient factors in the utilization of antenatal care services among expectant mothers in Kyotera and Rakai Districts , Uganda.,b. To assess patient factors influencing mobile telephone communication among expectant mothers in Kyotera and Rakai Districts, Uganda.,a. To examine effects of mobile telephone communication on the utilization of antenatal care services among expectant mothers in Kyotera and Rakai Districts, Uganda.,
|
Rakai, Kitente
|
Uganda |
2022-01-12 |
2025-01-12 |
2214 |
THE STUDY POPULATION CONSTITUTES OF EXPECTANT MOTHERS AGED 15 TO 49 YEARS RESIDING IN KYOTERA AND RAKAI DISTRICTS FROM ALL THE TRIBES IN THESE COMMUNITIES. |
SELF SPONDORED |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
David Lubogo
ID: UNCST-2020-R014473
|
Metabolic Syndrome among Females of Reproductive age in Wakiso district, Central Uganda: Risk factors and Effectiveness of a Community based Nutrition Education Intervention
REFNo: HS1281ES
General objective: To investigate the prevalence of, and factors associated with metabolic syndrome (MetS) and evaluate the effect of a community based nutrition education intervention among females of reproductive age with MetS in Wakiso district, Central Uganda in order to contribute information for the design of interventions for MetS.
Specific objectives
1. To determine the prevalence of, and factors associated with Metabolic Syndrome.
2. To determine optimal WC cut off points for MetS.
3. To determine the effectiveness of a 12 -week community-based nutrition education and counseling intervention for metabolic syndrome on selected cardiovascular outcomes (BP), biochemical outcomes (HDL, TGS, blood sugar), anthropometric measures (WC, weight), behavioral outcomes (dietary intake, physical activity), and on knowledge as an outcome.
4. To explore the female and health care provider perceptions/perspectives towards the nutrition promotion intervention on MetS among female of reproductive age in South Central Uganda.
|
Wakiso,
Wakiso,
|
Uganda |
2021-12-28 |
2024-12-28 |
840 |
Females aged 15- 49 years in Wakiso district. |
Strengthening Education and Training Capacity in Sexual and Reproductive Health and Rights in Uganda (SET-SRHR) and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
JIM ARINAITWE
ID: UNCST-2021-R012572
|
Quit4Life: Adapting and Evaluating a Phone-Based Tobacco Uses Cessation Program for People Living with HIV in Uganda and Zambia.
REFNo: HS1762ES
The goal of the study is to adapt and evaluate the efficacy of a phone-based tobacco cessation intervention for PLWH in Uganda and Zambia in five years. The primary objective of the study is to promote smoking cessation among HIV infected persons. Specifically, 1) adapt a standard short message service (SMS) for tobacco cessation program, 2) Nicotine Replacement Therapy, 3) compare the efficacy of our SMS-based program tailored to meet the needs of PLWH (Quit4Life+) to the current standard of care.
|
Arua, Adumi HCIV, Omugo HCIV and River Oli HCIV
Moroto, Loputuk HCIII, Nadunget HCIII and Tapac HCIII
|
Uganda |
2021-12-28 |
2024-12-28 |
Total Sample size is 800 with 400 from Uganda and 400 from Zambia |
The study will include males and females of consenting age attending HIV services at Health III, IV, District/Regional Referral Hospitals |
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JULIET MWANGA-AMUMPAIRE
ID: UNCST-2022-R009420
|
An open-label, multicentre, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
REFNo: HS1789ES
Primary objective: to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease
The secondary objectives are:
 To compare the safety of each study arm to control, up to Day 21 of follow-up
 To compare the rate of hospitalizations due to COVID-19 in each study arm versus control
 To compare the time to hospitalization due to COVID-19 in each study arm versus control
 To compare the rate of hospitalizations for other reason than Covid-19 in each study arm versus control
 To compare the disease-free rate in each study arm versus control
 To compare the death rate in each study arm versus control
 To compare time to worsening of SpO2 < 93in each study arm versus control
 To compare the capacity to prevent severe progression between study arms
 To identify risk factors for severe progression
 To assess efficacy in sub-groups of patients e.g. with pre-existing conditions/co-morbidities, by age group, sex, BMI, timeframe between onset of symptoms and randomization.
|
Mbarara, Mbarara Medical Cell
|
Uganda |
2021-12-07 |
2024-12-07 |
175 |
1. Male or female patients,
2. Adult’s  18 years of age at the time of screening. Children > 12 years of age may be included if recommended by the DSMB after the first analysis.
3. COVID-19 confirmed by molecular biology or validated antigenic test |
Drugs for Neglected Diseases Initiative (DNDi) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
PURPOSE 1: GS-US-412-5624/ A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection. Version 2.0, dated 10 March 2021.
REFNo: HS1920ES
1. Primary Objectives
i) To evaluate the efficacy of LEN for HIV PrEP in AGYW at risk of HIV infection.
ii) To evaluate the efficacy of F/TAF for HIV PrEP in AGYW at risk of HIV infection.
2. Secondary Objectives/ end points
i) To compare the efficacy of LEN with F/TDF for HIV PrEP in AGYW at risk of HIV infection.
ii) To evaluate the efficacy of LEN for HIV PrEP in AGYW at risk of HIV infection in participants adherent to LEN.
iii) To evaluate the efficacy of F/TAF for HIV PrEP in AGYW at risk of HIV infection in participants adherent to F/TAF.
iv) To compare the efficacy of F/TAF with F/TDF for HIV PrEP in AGYW at risk of HIV infection.
v) To evaluate the safety and tolerability of LEN, F/TAF, and F/TDF for HIV PrEP in AGYW at risk of HIV infection.
vi) To evaluate the safety and tolerability of LEN and F/TAF for HIV PrEP in AGYW ≥ 16 to < 18 years of age who have sex with male partners and are at risk for HIV infection.
3. Exploratory objectives
i) To assess the adherence rate to LEN as assessed by on-time LEN injection
ii) To assess LEN plasma levels
iii) To assess the adherence rate to F/TAF and F/TDF using intracellular TFV-DP levels in DBS.
iv) To evaluate the acceptability of a once every 26 weeks LEN injection for HIV PrEP in AGYW at risk of HIV infection.
v) To assess LEN plasma levels during pregnancy.
vi) To explore concentrations of hormonal contraceptives in LEN participants.
|
Mityana, Mityana
Hoima, Hoima county
Masaka, Masaka
Kalangala, Kalangala
|
Uganda |
2021-11-25 |
2024-11-25 |
The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a randomized blinded study (Randomized Phase). The Incidence Phase of the study will remain open until the backg |
Cisgender AGYW who have sex with male partners, at risk for HIV infection ≥ 16 to ≤ 25 years of age. |
Gilead Sciences Inc. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kamya Moses
ID: UNCST-2020-R014203
|
Enhancing immunity to malaria in young children with effective chemoprevention
REFNo: HS1763ES
To compare the incidence of malaria from 4 weeks to 4 years of age among children born to mothers randomized to receive intermittent preventative therapy in pregnancy (IPTp) with monthly sulfadoxine pyrimethamine (SP) alone, monthly DP alone, or both monthly SP+DP.
To compare the incidence of malaria from 2-4 years of age among children randomized to receive IPT in childhood (IPTc) with monthly DP from 8 weeks to 1 year of age vs. monthly DP from 8 weeks to 2 year of age vs. no IPTc.
To compare innate and adaptive effector and regulatory responses between children randomized to different IPT arms.
|
Busia, Masafu
|
Uganda |
2021-11-24 |
2024-11-24 |
924 HIV-uninfected infants |
Children both male and female, 4 weeks to 4 years of age, resident of Busia District |
Division of Microbiology and Infectious Diseases (DMID) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19
(Adapt Out COVID)
REFNo: HS1813ES
1.1 Co-Primary Objectives
1.1.1 Phases II and III: To evaluate safety of the investigational agent.
1.1.2 Phase II: To determine efficacy of the investigational agent to reduce the duration of COVID-19 symptoms through study day 28.
1.1.3 Phase II: To determine the efficacy of the investigational agent to increase the proportion of participants with nasopharyngeal (NP) SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) at study days 3, 7, and 14.
1.1.4 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study day 28. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19 during the COVID-19 pandemic.
1.2 Secondary Objectives
1.2.1 Phases II and III: To determine whether the investigational agent reduces a COVID-19 Severity Ranking scale based on COVID-19-associated symptom burden (severity and duration), hospitalization, and death, through study day 28.
1.2.2 Phase II and III: To determine whether the investigational agent reduces the progression of COVID-19-associated symptoms.
1.2.3 Phase II and III: To determine if the investigational agent reduces levels of SARS-CoV-2 RNA in NP swabs.
1.2.4 Phase III: To determine the efficacy of the investigational agent to increase the proportion of participants with NP SARS-CoV-2 RNA below the LLoQ at study day 3.
1.2.5 Phase II: To determine the pharmacokinetics of the investigational agent.
1.2.6 Phase II: To determine efficacy of the investigational agent to obtain pulse oximetry measurement of ≥96% through day 28.
1.2.7 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study week 72.
1.2.8 Phase III: To evaluate if the investigational agent reduces the time to sustained symptom resolution through study day 28.
|
Wakiso,
Mpigi,
Mukono,
|
Uganda |
2021-11-22 |
2024-11-22 |
The phase II evaluation will enroll approximately 110 participants per investigational agent (and 110 on placebo) (this includes all participants enrolled under previous protocol versions, irrespectiv |
Outpatient adults (≥18 years) with a documented positive SARS-CoV-2 molecular (nucleic acid) or antigen test from a sample collected ≤240 hours (10 days) prior to study entry and with ≤7 days of symptoms of COVID-19 at study entry, plus the presence |
The National Institute of Allergy and Infectious Diseases, Division of AIDS/NIAID/NIH/DHHS, Rockville, Maryland 20892 USA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Francis Ssali
ID: UNCST-2021-R012134
|
A Phase 2, Open-label, Single-arm, Multicentre Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to less than 12 years) who are Virologically Suppressed (TMC278HTX2002)
REFNo: HS1815ES
Primary Endpoints
• Area under the plasma concentration-time curve from the time of administration up to 24 hours post-dose of RPV, as derived from the intensive PK assessments.
• Incidence of grade 3/4 AEs, SAEs, HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment.
Secondary Endpoint
• Incidence and severity of AEs/HIV-related events and their relatedness to RPV through 24 and 48 weeks of study treatment.
• Change from baseline Movement.
• Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.
• Treatment adherence, as assessed by the Pediatric European Network for the Treatment of AIDS (PENTA) adherence questionnaire and by study intervention accountability, through 24 and 48 weeks of study treatment.
|
Wakiso, Makindye
,
|
Uganda |
2021-11-22 |
2024-11-22 |
lower limit is 3 and Upper limit is 10 |
Participants (boys and girls) aged ≥2 to <12 years with a bodyweight of at least 11 kg |
Janssen Sciences Ireland Unlimited Company |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jerome Kabakyenga Kahuma
ID: UNCST-2021-R013729
|
The A-Lite vein locator: “a non-invasive assistive medical device designed to improve vein visibility among patients requiring intravenous therapy.â€
REFNo: HS1547ES
Main Objective
1. To assess the efficacy, safety and impact of using an assistive medical device to aid vein visibility among patients requiring intravenous therapy.
Specific Objectives
1. To assess the safety and efficacy of the A-Lite vein locator among 10 adults in Uganda.
2. To investigate non-inferiority by assessing the performance of the A-Lite vein locator with respect to the existing standard of care among 48 adolescents in Uganda.
3. To determine the effectiveness of using the A-Lite vein locator for improving vein visibility among 156 children requiring intravenous cannulation in Uganda.
|
Kalungu, Bugonzi
Lira, Junior Quarters
Mbarara, Rwebishekye
Isingiro, Kashojwa
|
Uganda |
2021-11-19 |
2024-11-19 |
214 |
Ages eligible for the study: 1 up to 30 years
Sexes eligible for the study: All
|
International Development Research Centre (IDRC) – Canada and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
ANGELLA MUSIIMENTA
ID: UNCST-2021-R013297
|
My Mobile Wallet: An Intervention to Support Access to Tuberculosis Care and medication Adherence in Rural Uganda
REFNo: HS1688ES
Assess the refined My Mobile Wallet intervention for larger scale feasibility, acceptability, and impact on TB treatment adherence and clinical outcomes. We will randomize 162 newly diagnosed TB patients (1:1:1) to SMS texts + incentives Arm A, SMS texts only B, and control Arm C (standard clinic-based TB care); follow-up will be the 6 month-treatment period. Feasibility and acceptability will be assessed per above. Impact will be based on electronically monitored medication adherence (primary), as well as treatment completion, clinic attendance, cure, and mortality (secondary).,Refine the My Mobile Wallet intervention. We will adapt the intervention to address any feasibility and accessibility issues raised in R21 findings. We will then pilot test the refined version of the intervention in 10 TB patients over two months of treatment to ensure optimal functionality. ,Assess the initial feasibility and acceptability of My Mobile Wallet. Forty patients with newly diagnosed TB will use My Mobile Wallet over their 6-month course of treatment. Feasibility will be assessed by appropriate receipt of the cash transfers and SMS texts, and intervention functionality. Acceptability will be assessed using System Usability Scale [53] and interviews based on the Unified Theory of Acceptance and Use of Technology [54].,Determine the optimal design and develop My Mobile Wallet as an intervention to support TB medication adherence. Through client-centered approaches, we will iteratively conduct focus group discussions with up to 30 TB patients to develop an optimal My Mobile Wallet intervention.,
|
Mbarara, Kamukuzi
Mbarara,
|
Uganda |
2021-11-19 |
2024-11-19 |
242 |
TB patients (18 and above years old) living not beyond 60 Kilometers from MRRH who are willing to participate in the study |
US National Institute of Health (Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Adeodata Rukyalekere Kekitiinwa
ID: UNCST-2019-R000799
|
BREATHER Plus: A randomized open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir- based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa, Version 2.0, Dated 18-Mar-2020; ISRCTN #: 85058577
REFNo: HS1822ES
Major Objective: A randomized open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub- Saharan Africa
Specific Objectives
To evaluate an innovative and contemporary ART strategy in HIV-infected adolescents to provide choice for young people facing life-long treatment. Output from this RCT will provide evidence on efficacy, safety and acceptability of a novel treatment approach in HIV-infected adolescents in sub-Saharan Africa
To evaluate the virological efficacy, safety, acceptability and Quality of Life of DTG-based Short-cycle Therapy with weekends off compared with Continuous Therapy with a DTG- based ART regimen
To optimize treatment for HIV-infected adolescents in sub-Saharan Africa
|
Kampala, Mulago
Wakiso, Seguku
|
Uganda |
2021-11-15 |
2024-11-15 |
460 |
HIV-infected, non-pregnant, non-breastfeeding adolescents aged 12 to 19 years of age, virologically-suppressed for at least one year, without any history of treatment failure, on 3-drug combination antiretroviral (ART) consisting of dolutegravir with a 2- |
University College London (UCL), UK and funded by the European and Developing Countries Clinical Trials Partnership [RIA2017MC- 2005] |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Namulema Edith
ID:
|
Effectiveness of the ‘LeVe CPAP’ against the standard AIRVO CPAP among Covid-19 patients with Acute Hypoxemic Respiratory Failure at Mengo Hospital Kampala Uganda: A Cross-Over Randomised Trial.
REFNo: HS1647ES
The main objective of the trial is to compare the clinical effectiveness of the LeVe CPAP device to the standard AIRVO CPAP in the delivery and maintaining continuous positive airway pressures among patients diagnosed with AHRF at Mengo Hospital Uganda.
|
Kampala, mengo
|
Uganda |
2021-10-28 |
2024-10-28 |
40 |
Male and Female Adult patients with evidence of acute hypoxaemic respiratory failure admitted at the CTU. Any Tribe. |
Leeds Teaching Hospital National Health Service Trust in the UK |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
